5 top psoriatic disease discoveries of 2016
Learning about the latest research in psoriatic disease can be overwhelming, but staying up to date on your treatment options can help you make more informed health decisions to ultimately take better control of your disease.
With that said, it can sometimes feel like the more you learn about the disease, the more you end up worrying about another comorbidity (a related health condition) or treatment side effect you could experience.
But 2016 was a busy year for research that included plenty of significant advances in treatment options, U.S. Food and Drug Administration (FDA) approvals and discoveries that could lead to a brighter future for people living with psoriatic disease.
As we embark on 2017, let’s reflect on five highlights in psoriatic disease research over the past year. Keep in mind there have been many recent discoveries and advancements in psoriatic disease, and this list is by no means all-inclusive of the many novel, innovative and exciting research developments in 2016.
1. New FDA drug approvals expanded treatment options for psoriasis and psoriatic arthritis.
The year started off with a new drug approval for psoriatic arthritis. Cosentyx (secukinumab), made by Novartis, received U.S. Food and Drug Administration (FDA) approval for the treatment of psoriatic arthritis. Learn more about Cosentyxhere.
In March 2016, the FDA approved Taltz (ixekizumab), a biologic drug manufactured by Eli Lilly, for the treatment of moderate to severe plaque psoriasis.
Taltz had promising results in clinical trials where more than a third of patients had completely clear skin after three months on the treatment. Click here for more information on Taltz.
For the first time, the FDA approved a biologic medication for the treatment of pediatric plaque psoriasis. Enbrel (etanercept), a drug made by Amgen, was one of the earliest biologics on the market since it was first approved for the treatment of psoriasis in adults in 2004.